(S)-5-(3-benzylpiperazin-1-yl)-8-methoxy-2-(trifluoromethyl)quinoline 、 5-甲基-4H-1,2,4-三唑-3-乙酸 以to afford the title compound as colorless solid (17 mg, 12%)的产率得到(S)-1-(2-benzyl-4-(8-methoxy-2-(trifluoromethyl)quinolin-5-yl)piperazin-1-yl)-2-(3-methyl-1H-1,2,4-triazol-5-yl)ethanone
参考文献:
名称:
Therapeutic piperazines
摘要:
该发明涉及公式 I 的化合物:其中 R1,Y,A,n,R4和Z具有本文所述的任何值,以及这些化合物的盐,包含这些化合物的组合物和包含这些化合物的治疗方法。这些化合物是PDE4功能的抑制剂,可用于改善认知功能和/或治疗动物(尤其是人类)的认知障碍或损伤、中枢和外周神经系统的创伤和/或缺血性损伤以及/或精神障碍。
The invention includes a compound of formula I:
wherein R1, Y, A, n, R4 and Z have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of PDE4 function and are useful for improving cognitive function and/or treating cognitive disorders or impairment, traumatic and/or ischemic injuries of the central and peripheral nervous system and/or psychiatric disorders in animals, especially humans.
该发明涉及公式 I 的化合物:其中 R1,Y,A,n,R4和Z具有本文所述的任何值,以及这些化合物的盐,包含这些化合物的组合物和包含这些化合物的治疗方法。这些化合物是PDE4功能的抑制剂,可用于改善认知功能和/或治疗动物(尤其是人类)的认知障碍或损伤、中枢和外周神经系统的创伤和/或缺血性损伤以及/或精神障碍。
WO2007/64553
申请人:——
公开号:——
公开(公告)日:——
Synthesis and study of novel 1,2,4-triazolylacetic acid derivatives
作者:Dmitro M. Khomenko、Roman O. Doroshchuk、Oleksandr V. Vashchenko、Rostyslav D. Lampeka
DOI:10.1007/s10593-016-1901-z
日期:2016.6
A range of 1,2,4-triazolylacetic acids and their derivatives with various substituents at the triazole ring position 3 have been synthesized. The properties of the obtained compounds were studied, showing that: 1) triazolylacetic esters are strong acylating agents; 2) all the obtained triazolylacetic acids underwent decarboxylation when heated to the melting point; 3) the CH2 group in the acetyl moiety
The invention includes a compound of formula I:
wherein R
1
, Y, A, n, R
4
and Z have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of PDE4 function and are useful for improving cognitive function and/or treating cognitive disorders or impairment, traumatic and/or ischemic injuries of the central and peripheral nervous system and/or psychiatric disorders in animals, especially humans.